black box warning semaglutide The U.S. health regulator asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. https://cnn.it/49uSrKw Popular weight-loss drugs shouldn't carry

New tachycardia in the early post-operative period must be treated as a potential surgical emergency anastomotic leak, haemorrhage, and pulmonary embolism must be excluded urgently

Back Park, A (15 March 2024) 'GLP-1s on track to take drug sales throne from PD-1 inhibitors in 2024', Fierce Pharma

Minimization of patient-reported AEs may facilitate patient adherence

54.5%) in the year following their PMOS diagnosis compared to non-initiators

The product comes in capsule form with a recommended dose of two capsules daily, taken with the largest meal of the day

Products will only be used for legitimate research purposes